AI assistant
CANN GROUP LIMITED — Investor Presentation 2021
Feb 18, 2021
64603_rns_2021-02-18_475046ed-ec0f-4b9f-9882-5a1b6dcd2db9.pdf
Investor Presentation
Open in viewerOpens in your device viewer
==> picture [585 x 60] intentionally omitted <==
ASX ANNOUNCEMENT
19 February 2021
CANN GROUP FY21 HALF YEAR RESULTS INVESTOR WEBINAR
19 February 2021 – Cann Group Limited (ASX: CAN) ( Cann or the Company ) is pleased to announce it will hold an investor webinar on Monday 22 February 2021 at 1:30pm AEDT with CEO Peter Crock and COO Shane Duncan to discuss the FY21 Half Year Results.
Investors are invited to send questions prior to the webinar to [email protected]
Register for the investor webinar at the link below:
After registering, you will receive a confirmation email containing information about joining the webinar. A recording will be made available shortly after the conclusion of the webinar at the same link.
To join the webinar via telephone, please use one of the following numbers and enter the Webinar ID: 896 8724 8438
For higher quality, dial a number based on your current location:
+61 8 6119 3900 or +61 8 7150 1149 or +61 2 8015 6011 or +61 3 7018 2005 or
+61 7 3185 3730
International numbers available: https://us02web.zoom.us/u/kvsfa5uem
Authorised for release by the Company Secretary, Cann Group Limited.
For further information please contact:
Peter Crock Clive Fanning Matthew Wright CEO Head of Investor Relations NWR Communications Cann Group Limited Cann Group Limited +61 451 896 420 +61 3 9095 7088 +61 3 9095 7088 [email protected] [email protected] [email protected]
About Cann Group
Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. The company has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has executed collaboration agreements that have enabled it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of locally sourced and manufactured medicinal cannabis products. Learn more about Cann Group at www.canngrouplimited.com
Cann Group Limited ACN 603 949 739 4 Research Avenue, Bundoora, VIC 3083 Australia Ph: +61 3 9095 7088